Product Name:    Flibanserin

Synonyms:    Niemunerkeine;3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1H-benzimidazol-2-one;Flibaneserin;BIMT-17;BIMT-17BS;Flubensin (female);Flibaserin(female);Fbanselin;Flubanserin

CAS:    167933-07-5

MF:    C20H21F3N4O

MW:    390.4

EINECS:    643-002-2

Product Categories:    API;API,chemical material

Flibanserin (Addyi-Sprout Pharmaceuticals) is a first-in-class oral medication approved by FDA for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Although it meets the need for drugs that address women's sexual function, flibanserin is unlike agents that treat erectile dysfunction, as it is intended to increase sexual desire, not performance.

Flibanserin is the first prescription medicine for the treatment of this sexual dysfunction. The FDA approval is not without warnings; flibanserin is subject to the Risk Evaluation and Mitigation Strategy (REMS) to ensure safe use by patients, and has a boxed warning directed to prescribing providers. The goal is to inform patients and providers of the increased risk of hypotension and syncope (Vallejos 2017).